Fuan Pharmaceutical (Group) Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Fuan Pharmaceutical (Group) has been growing earnings at an average annual rate of 11.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 0.7% per year. Fuan Pharmaceutical (Group)'s return on equity is 6.4%, and it has net margins of 10.6%.
Wichtige Informationen
11.2%
Wachstumsrate der Gewinne
10.5%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 10.9% |
| Wachstumsrate der Einnahmen | 0.7% |
| Eigenkapitalrendite | 6.4% |
| Netto-Marge | 10.6% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Shares Fly 36% But Investors Aren't Buying For Growth
Oct 08
There's No Escaping Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Muted Earnings
Aug 23Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?
Jun 07Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit
May 02Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price
Apr 03Aufschlüsselung der Einnahmen und Ausgaben
Wie Fuan Pharmaceutical (Group) Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 2,660 | 282 | 897 | 145 |
| 30 Jun 24 | 2,752 | 287 | 968 | 150 |
| 31 Mar 24 | 2,766 | 268 | 992 | 154 |
| 31 Dec 23 | 2,648 | 232 | 1,018 | 149 |
| 30 Sep 23 | 2,621 | 320 | 1,020 | 156 |
| 30 Jun 23 | 2,600 | 278 | 1,088 | 145 |
| 31 Mar 23 | 2,560 | 253 | 1,104 | 144 |
| 01 Jan 23 | 2,422 | 205 | 1,096 | 143 |
| 30 Sep 22 | 2,411 | -339 | 1,145 | 126 |
| 30 Jun 22 | 2,382 | -316 | 1,137 | 128 |
| 31 Mar 22 | 2,357 | -321 | 1,171 | 124 |
| 01 Jan 22 | 2,453 | -297 | 1,221 | 120 |
| 30 Sep 21 | 2,374 | 192 | 1,271 | 99 |
| 30 Jun 21 | 2,428 | 184 | 1,308 | 96 |
| 31 Mar 21 | 2,446 | 203 | 1,280 | 93 |
| 31 Dec 20 | 2,368 | 209 | 1,236 | 87 |
| 30 Sep 20 | 2,490 | 263 | 1,225 | 111 |
| 30 Jun 20 | 2,530 | 272 | 1,234 | 111 |
| 31 Mar 20 | 2,627 | 287 | 1,305 | 105 |
| 31 Dec 19 | 2,781 | 293 | 1,369 | 108 |
| 30 Sep 19 | 2,729 | -363 | 1,328 | 117 |
| 30 Jun 19 | 2,647 | -380 | 1,255 | 118 |
| 31 Mar 19 | 2,633 | -375 | 1,201 | 123 |
| 31 Dec 18 | 2,669 | -360 | 1,208 | 120 |
| 30 Sep 18 | 2,661 | 277 | 1,215 | 108 |
| 30 Jun 18 | 2,583 | 276 | 1,133 | 139 |
| 31 Mar 18 | 2,403 | 283 | 975 | 113 |
| 31 Dec 17 | 2,091 | 285 | 719 | 97 |
| 30 Sep 17 | 1,904 | 303 | 539 | 58 |
| 30 Jun 17 | 1,742 | 320 | 421 | 0 |
| 31 Mar 17 | 1,535 | 281 | 357 | 0 |
| 31 Dec 16 | 1,297 | 222 | 311 | 0 |
| 30 Sep 16 | 1,069 | 171 | 286 | 0 |
| 30 Jun 16 | 909 | 121 | 274 | 0 |
| 31 Mar 16 | 799 | 86 | 259 | 0 |
| 31 Dec 15 | 708 | 65 | 226 | 0 |
| 30 Sep 15 | 631 | 57 | 184 | 0 |
| 30 Jun 15 | 514 | 40 | 134 | 0 |
| 31 Mar 15 | 459 | 38 | 105 | 0 |
| 31 Dec 14 | 449 | 46 | 101 | 0 |
| 30 Sep 14 | 430 | 50 | 95 | 0 |
| 30 Jun 14 | 409 | 49 | 94 | 0 |
| 31 Mar 14 | 372 | 39 | 90 | 0 |
| 31 Dec 13 | 358 | 38 | 89 | 0 |
Qualität der Erträge: 300194 has high quality earnings.
Wachsende Gewinnspanne: 300194's current net profit margins (10.6%) are lower than last year (12.2%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 300194 has become profitable over the past 5 years, growing earnings by 11.2% per year.
Beschleunigtes Wachstum: 300194's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 300194 had negative earnings growth (-12.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 300194's Return on Equity (6.4%) is considered low.